CR Double-Crane(SH:600062) Xin Lang Cai Jing·2025-11-18 09:52Core Viewpoint - The National Medical Products Administration (NMPA) emphasizes the importance of ensuring the quality and safety of drugs selected through centralized procurement, highlighting the need for strict compliance and quality control by selected companies [1] Group 1: Regulatory Oversight - The NMPA will implement comprehensive production inspections and product sampling for selected drugs, ensuring full coverage in regulatory practices [1] - Regulatory bodies will optimize work mechanisms and explore risk monitoring to enhance oversight and prevent potential risks [1] Group 2: Company Responsibilities - Selected companies are required to strictly fulfill their primary responsibilities, focusing on quality control, drug vigilance, and information traceability [1] - Continuous compliance in production practices is mandated for companies involved in centralized procurement [1]